EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials

Linde Hoosemans, Marc Vooijs iD, Ann Hoeben iD

Cancers · 29.08.2024 · 16 (17) · 3021

DOI: 10.3390/cancers16173021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.08.2024. Verfasst von Linde Hoosemans und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Center+, 6229 HX Maastricht, The…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most prevalent central nervous system tumour (CNS). Patients with GBM have a dismal prognosis of 15 months, despite an intensive treatment schedule consisting of surgery, chemoradiation and concurrent chemotherapy. In the last decades, many trials have been performed investigating small molecule inhibitors, which target specific genes involved in tumorigenesis. So far, these trials have been unsuccessful, and standard of care for GBM patients has remained the same since 2005. This review gives an overview of trials investigating small molecule inhibitors on their own, combined with chemotherapy or other small molecule inhibitors. We discuss possible resistance mechanisms in GBM, focussing on intra- and intertumoral heterogeneity, bypass mechanisms and the influence of the tumour microenvironment. Moreover, we emphasise how combining inhibitors can help overcome these resistance mechanisms. We also address strategies for improving trial outcomes through modifications to their design. In summary, this review aims to elucidate different resistance mechanisms against small molecule inhibitors, highlighting their significance in the search for novel therapeutic combinations to improve the overall survival of GBM patients.

Schlagwörter

Stichwörter der Autor:innen

clinical trialsglioblastomaresistancesmall molecule inhibitorstyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.
  • Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.

ORCID-Profile: Marc Vooijs, Ann Hoeben

Förderung

  • KWF Dutch Cancer Society

Zitieren

APA

Hoosemans, L., Vooijs, M., & Hoeben, A. (2024). Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials. Cancers, 16(17), 3021. https://doi.org/10.3390/cancers16173021

Vancouver

Hoosemans L, Vooijs M, Hoeben A. Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials. Cancers. 2024;16(17):3021. doi:10.3390/cancers16173021

BibTeX
@article{Hoosemans2024,
  author = {Hoosemans, Linde and Vooijs, Marc and Hoeben, Ann},
  title = {Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {17},
  pages = {3021},
  doi = {10.3390/cancers16173021}
}
Kostenlos starten →